Fundamental Analysis of AcelRx Pharmaceuticals Inc - Growth / Value Index
ACRX - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 5.00
Price to Book Ratio of 352039 suggesting that it is very expensive
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -755768.51 | -597.22 | -430555.53 % | |
| Price to Book | 352039 | 904.57 | 297720 % | 1.08 |
| Price to Sales | 5764040 | 5959.33 | 159191 % | |
| Enterprise Value to EBITDA Multiple | -0.622 | -626.63 | -2672932.08 % |
ACRX - Profitability Highlights
Profitability Analysis
Piotroski F Score - Stable Value of 5.0
Tsr Profitability Index - Very Poor Score of 5.00
Very Low Dividend Yield of 0 %
EPS decline for last four quarters
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -46.58 | -151.46 | -169.19 % | -32.02 |
| Return On Asset | -26.23 | -104.75 | -204.16 % | -22.15 |
| Net Profit Margin | -762.67 | -997.85 | -137.01 % | -1607.47 |
| Operating Profit Margin | -2594.32 | -1390.85 | 32.76 % | -1524.20 |
| EBITDA Margin | -2330.41 | -950.58 | -133.29 % | -1607.47 |
Highlights
| Market Cap | 15163.83 K |
| Enterprise Value | 9442.83 K |
| Price/Book TTM | 352039 |
| Outstanding Share | 16952.30 K |
| Float/ Outstanding Share | 70.96% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 5.00 |
| Altman Z Score | -31.87 |
| Sloan Ratio | -0.118 |
| Peter Lynch Fair Value | 0 |
ACRX - Growth Highlights
Growth Analysis
Tsr Growth Index - Poor Score of 26.72
Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 651000 | 20.89 % | 140.17 % |
| Gross Profit | -676999.00 | 179.39 % | 100.00 % |
| EBITDA | -15171.00 K | 140.25 % | 232.87 % |
| Net Profit | -4965.00 K | 144.74 % | 232.87 % |
| EPS | 0 | 100.02 % | NA |
ACRX - Stability Highlights
Stability Analysis
Tsr Stability Index - Good Score of 69.64
Company is Debt Free
Net Debt zero balance-sheet with high liquidity
Altman Z Score of -31.87 suggest high risk
Company is unable to generate enough free cash to support the business.
Interest Coverage of -58.51
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0 | 0 % | 0 |
| Cash Ratio | 2.08 | 81.54 % | |
| Quick Ratio | 0 | 0 % | 2.56 |
| Shareholders Equity | 69.16 | 50.55 % | |
| Debt to EBITDA | 0 | 0 % |
Historical Valuation Ratios of AcelRx Pharmaceuticals Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of AcelRx Pharmaceuticals Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of AcelRx Pharmaceuticals Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of AcelRx Pharmaceuticals Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)